Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Ascletis Pharma, Inc. ( (HK:1672) ) is now available.
Ascletis Pharma Inc. announced that its weight loss drug candidate, ASC47, in combination with semaglutide, showed a significant reduction in body weight in obese participants compared to semaglutide alone. The study demonstrated better gastrointestinal tolerability and a lower rebound effect after treatment discontinuation, suggesting ASC47’s potential as a maintenance therapy. These findings could enhance Ascletis’s positioning in the weight management sector, offering a promising option for obesity treatment.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$10.50 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
More about Ascletis Pharma, Inc.
Ascletis Pharma Inc. is a biopharmaceutical company focused on the development of innovative drugs for the treatment of liver diseases, viral infections, and cancer. The company is known for its research and development in muscle-preserving weight loss drug candidates and other therapeutic areas.
Average Trading Volume: 8,694,374
Technical Sentiment Signal: Buy
Current Market Cap: HK$10.67B
See more data about 1672 stock on TipRanks’ Stock Analysis page.